Antibe Therapeutics Announces Upcoming Conference Schedule

TORONTO–(BUSINESS WIRE)–Antibe Therapeutics Inc. (“Antibe” or the “Company”) (TSXV: ATE, OTCQB:
ATBPF), a leader in developing safer therapeutics for pain and
inflammation, is pleased to announce its conference schedule for the
upcoming months.

2019 BIO International Convention (June 3 –
6, 2019) – Philadelphia, United States

Antibe will be engaging in several days of one-on-one meetings with
pharmaceutical companies to discuss licensing and partnering
opportunities for Antibe’s lead drug, ATB-346. BIO International is the
largest biopharma partnering event of the year, attracting over 16,000
leaders and business development executives from 5,000 companies across
the globe.

9^th Annual LD Micro Invitational (June 4 –
5, 2019) – Los Angeles, United States

Antibe’s CEO, Dan Legault, has been invited to present at the LD Micro
investor conference on Tuesday, June 4^th, 2019 at 9:40 am
(Pacific Time) at the Luxe Hotel in Los Angeles, California. The LD
Micro Invitational will feature 250 companies and will be attended by
over 1,000 individuals.

European Congress of Rheumatology 2019 (June 12 – 15, 2019) – Madrid,
Spain

Antibe’s Chief Scientific Officer, John Wallace, will be representing
Antibe at Europe’s major conference for osteoarthritis organized by the
European League Against Rheumatism (EULAR). EULAR promotes the
translation of research advances into daily care and fights for the
recognition of the needs of people with musculoskeletal diseases by the
governing bodies in Europe.

TSX Venture 50 Capital Conference (July 11 – 13, 2019) – Kelowna,
Canada

Antibe will be participating in the TSX Venture 50 Capital Conference,
an investor networking event that includes one-on-one meetings
exclusively for this year’s TSX Venture 50 winners. Antibe was ranked
second in the Clean Technology and Life Sciences sector on the TSX
Venture Exchange based on its performance last year.

In addition, the Company has amended its agreement with MKR Group, Inc.
(“MKR”), a California-based investor relations firm, reflecting a
monthly retainer of US$7,000 (per a revised agreement in 2018). MKR will
continue to broaden awareness of Antibe amongst institutional investors
and sell-side analysts in the United States. The engagement can be
terminated by either party upon 30 days notice.

About Antibe Therapeutics Inc.

Antibe develops safer, non-addictive medicines for pain and
inflammation. Antibe’s technology involves linking a hydrogen
sulfide-releasing molecule to an existing drug to produce a patented,
improved medicine. Antibe’s lead drug ATB-346 targets the global need
for a safer, non-addictive drug for chronic pain and inflammation.
ATB-352, the second drug in Antibe’s pipeline, targets the urgent global
need for a non-addictive analgesic for treating severe acute pain, while
ATB-340 is a GI-safe derivative of aspirin. Citagenix Inc., an Antibe
subsidiary, is a market leader and worldwide distributor of regenerative
medicine products for the dental marketplace. www.antibethera.com.

Forward Looking Information

This news release includes certain forward-looking statements, which may
include, but are not limited to, the completion of financing
transactions and the licensing and development of drugs and medical
devices. Any statements contained herein that are not statements of
historical facts may be deemed to be forward-looking, including those
identified by the expressions “will”, “anticipate”, “believe”, “plan”,
“estimate”, “expect”, “intend”, “propose” and similar expressions.
Forward-looking statements involve known and unknown risks and
uncertainties that could cause actual results, performance, or
achievements to differ materially from those expressed or implied in
this news release. Factors that could cause actual results to differ
materially from those anticipated in this news release include, but are
not limited to, the Company’s ability to secure additional financing,
its ability to execute its business strategy and successfully compete in
the market, and risks associated with drug and medical device
development generally. Antibe Therapeutics Inc. assumes no obligation to
update the forward-looking statements or to update the reasons why
actual results could differ from those reflected in the forward-looking
statements except as required by applicable law.

Contacts

Antibe Therapeutics Inc.
Dan Legault
Chief Executive Officer
(416)
473 4095
[email protected]